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Background: “Dragon’s Blood” (DB) has long been used as an ethnomedicine in China to invigorate blood
circulation for the treatment of traumatic injuries, blood stasis and pain. To comprehensively assess the quality of
DB medicine, a precise and accurate method that can rapidly separate, characterize and quantify multiple active
components of DB is crucial.
Results: An ultra performance liquid chromatography (UPLC) coupled with photodiode array detection (PAD) and
electrospray ionization mass spectrometry (ESI-MS) method was developed for characterization and determination
of six flavonoids in DB. A comprehensive validation of the developed method was conducted, and confirmed that
the method presented good sensitivity, precision and accuracy. All linear regressions were acquired with R2 > 0.99,
and the limits of detection ranged from 0.06 to 0.83 ng. The relative standard deviation (RSD) values were found to
be within the range 1.4–3.8% for the method repeatability test. Recovery studies for the quantified compounds
were found to be within the range 94.2–102.8% with RSD less than 4.9%. DB samples collected from different
geographical regions were analyzed by the present method, and the results demonstrated that the contents of the
six flavonoids in DB samples varied significantly. Three major active components among the six flavonoids, namely
dracorhodin, (2S)-5-methoxyflavan-7-ol and (2S)-5-methoxy-6-methylflavan-7-ol, are suggested as the index for DB
quality evaluation.
Conclusions: Overall, the present hyphenation method is highly efficient and reliable, and hence suitable for the
characterization and determination of the flavonoids of DB ethnomedicine.
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“Dragon’s Blood” (DB), a deep red resin secreted from
the fruit of the Daemonorops draco tree, has long been
used as an ethnomedicine in China to invigorate blood
circulation for the treatment of traumatic injuries, blood
stasis and pain [1,2]. Flavonoids [3,4] and resin terpenoid
acids [5,6] are the main constituents of DB. Currently,
the quality evaluation for DB medicine is based on the
content of only one marker compound, namely dracor-
hodin, which is one of the bioactive compounds identi-
fied so far in DB [1].* Correspondence: hbchen@hkbu.edu.hk
School of Chinese Medicine, Hong Kong Baptist University, Hong Kong
Special Administrative Region, P. R. China
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reproduction in any medium, provided the orIn recent years, pharmacologic studies have demon-
strated that DB medicine exerts its clinical effects by
inhibiting blood platelet aggregation [2,7], and more com-
ponents of DB have been found to be active in this
process. For example, it is reported that the raw extract of
DB dose-dependently inhibits myocardial ischemia and
thrombus formation of the rats, and the coagulation time is
extended significantly [8]. (2S)-5-methoxy-6-methylflavan-
7-ol, a flavonoid isolated from DB, dose-dependently
inhibits aggregation of washed rabbit platelets induced by
collagen, arachidonic acid and adenosine diphosphate
(ADP) [9].
It is widely known that multiple constituents are prob-
ably involved in any herb’s therapeutic functions, and
that the content of a single marker compound cannot
accurately reflect the quality of herbal products [10,11].d. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://journal.chemistrycentral.com/content/6/1/116Thus, for DB as an herbal medicine, a novel quality evalu-
ation standard based on the contents of multiple active
components is needed to comprehensively assess its quality.
However, accurate means for qualitative and quantitative
analysis of the multiple components simultaneously have
not been reported, even though the determination of dra-
corhodin in DB has been carried out by TLC [12], HPLC
[13] and CE [14], respectively. Therefore, a method for the
simultaneous characterization and determination of the
major active components in herbal medicines in general
and DB in particular is still a top priority for accurate qua-
lity evaluation.
In the present study, a method coupling ultra-performance
liquid chromatography (UPLC) with photodiode array
detection (PAD) and electrospray ionization mass spec-
trometry (ESI-MS) was developed for the characterization
and determination of six flavonoids in DB medicine. The
validation results revealed that the developed method is
highly efficient and reliable, and hence suitable for qualitative
and quantitative analysis of DB samples. Based on the sam-
ple assay results, three major active components among the
six flavonoids, namely dracorhodin, (2S)-5-methoxyflavan-
7-ol and (2S)-5-methoxy-6- methylflavan-7-ol, are suggested
as the index for quality evaluation of DB medicine.Experimental
Materials
“Dragon’s Blood” (DB) samples were collected from vari-
ous regions of China. Identity of the samples was con-
firmed by the authors, and voucher specimens were













Figure 1 Chemical structures of the identified components in the UPLReagents and chemicals
Analytical grade methanol (Labscan, Bangkok, Thailand)
was used for preparation of standards and sample extraction.
Chromatographic grade acetonitrile (Labscan, Bangkok,
Thailand), chromatographic grade formic acid (Fluka, Buchs,
Switzerland) and deionized water obtained from a Milli-Q
water purification system (Millipore, Bedford, MA, USA)
were used for preparation of the mobile phase.
The standard compound of dracorhodin perchlorate
was purchased from the National Institutes for Food and
Drug Control (Beijing, China). 4, 6-dihydroxy-2-methoxy-
3-methyldihydrochalcone, 4, 6- dihydroxy-2-methoxyv-
3-methylchalcone, (2S)-5,7-dihydroxy-dihydroflavone,
(2S)-5-methoxyflavan- 7-ol and (2S)-5-methoxy-6-methyl-
flavan-7-ol were isolated by our laboratory with a purity of
more than 98%, and their chemical structures were eluci-
dated by comparing them with published data of 1H and
13C NMR [15-17]. Details of their separation and structural
elucidation will be reported elsewhere. Their chemical
structures are shown in Figure 1.Preparation of standard and sample solutions
The stock solutions of six standard compounds were
prepared in methanol and stored in the refrigerator. The
working solutions were prepared by appropriate dilution
of the stock solutions with methanol, and the resulting
concentration ranges are listed in Table 1.
DB sample powder (0.1 g) was extracted with 10 mL of
methanol by means of sonication at room temperature for
0.5 h. Sampling weight of DB is adjusted if necessary. The
operations were repeated once, and the residue was washed















Table 1 Linearity curves, LOD and LOQ for six compounds
Peak Compounds Linear equations Range (μg/mL) R2 LOD (ng) LOQ (ng)
1 Dracorhodin y = 8580.5x + 8536.8 5-250 0.9998 0.48 1.60
2 4,6-Dihydroxy-2-methoxy-3- methyldihydrochalcone y = 6472.4x + 1430.2 1-50 0.9982 0.15 0.50
3 4,6-Dihydroxy-2-methoxy-3- methylchalcone y = 6529.5x - 2240.9 1-50 0.9999 0.52 1.73
4 (2S)-5,7-Dihydroxy- dihydroflavone y = 25710.1x + 14943.4 1-50 0.9989 0.06 0.20
5 (2S)-5-Methoxyflavan-7-ol y = 989.1x + 16685.5 20-1000 0.9992 0.83 2.76
6 (2S)-5-Methoxy-6-methyl- flavan-7-ol y = 4098.2x + 14161.0 5-250 0.9991 0.21 0.70
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http://journal.chemistrycentral.com/content/6/1/11625-mL volumetric flask, which was filled up to the calibra-
tion mark with extraction solvent. The extracts were then
filtered through a syringe filter (0.2 μm, Alltech, Beerfield,
IL, USA). An aliquot of 2 μL solution was injected for
UPLC-PAD-MS analysis.
UPLC-PAD-MS conditions
A Waters AcquityTM ultra performance liquid chromatog-
raphy (UPLC) system (Waters Corp., Milford, USA) with
photodiode array detection (PAD), was hyphenated to a
Bruker MicrOTOFQ system by an electrospray ionization
(ESI) interface (Bruker Daltonics, Bremen, Germany) for
chromatographic and mass spectrometric (MS) analysis.
Data analysis was conducted using DataAnalysis software
version 4.0 (Bruker Daltonics). For chromatographic sep-
aration, a Waters BEH C18 column (1.7 μm, 2.1 × 100
mm) with a VanGuardTM pre-column (BEH, C18, 1.7 μm,
2.1 × 5 mm) was used. The mobile phase consisted of
0.1% formic acid in water (A) and 0.1% formic acid in
acetonitrile (B) using a gradient program of 25% (B) in
0–2 min and 25-55% (B) in 2–15 min. The solvent flow
rate was 0.3 mL/min, the column temperature was set to
40°C, and the detection wavelength was 280 nm. The con-
ditions of MS analysis in the positive ion mode were as
follows: drying gas (nitrogen), flow rate, 8 L/min; gas
temperature, 180°C; scan range, 50–1600 m/z; end plate
offset voltage, -500 V; capillary voltage, 4500 V; nebulizer
pressure, 2.5 Bar.
Method validation and sample analysis
The calibration curve was established by plotting the peak
area against the concentrations of the standards with linear
regression analysis. The detection (LOD) and limit of quanti-
tation (LOQ) of the quantified constituents were visually
evaluated with a signal-to-noise ratio of about 3:1 and 10:1,
respectively. Instrumental precision was investigated by re-
peatedly analyzing the same mixed standard solution six
times, and the method repeatability was evaluated by six
replicated analyses of the same DB sample. Recovery of all
the quantified constituents was determined by samples at
different concentration levels using a mixture of standardswith 50, 100 and 200% of the quantified levels of constituents
in the DB sample. All DB samples collected from various
regions were analyzed using this method.
Results and discussion
Optimization of the extraction method and analysis
conditions
Compared to the reflux and soxhlet extraction, sonication
extraction was easier, while still satisfactory. The extraction
solvent was chosen from methanol, ethanol and their vari-
ous concentrations of aqueous solution. The results revealed
that extraction with absolute methanol produced the highest
yield for the desired analytes. Thus, methanol was chosen as
the solvent for the sample extraction. Extraction times and
cycles were further optimized, and the results demonstrated
that exhausted extraction could be achieved when DB sam-
ple powder of 0.1 g was extracted with 10 mL of methanol
by means of sonication for 0.5 h, twice.
The conditions for chromatographic analysis including
mobile phase composition, type of column, column
temperature and detection wavelength, were optimized
based on our previous study [18]. Acetonitrile was found to
be preferred over methanol as the mobile phase because it
gave better separation for the analytes at a lower column
pressure. Mobile phase gradients were compared on a HSS
C18 column and BEH C18 column at different temperatures.
The results showed that satisfactory separation could best
be obtained by eluting DB samples on a BEH C18 column
at 40°C using a linear gradient of acetonitrile and water
within 15 min. A wavelength of 280 nm was chosen to
monitor the analytes after comparing the chromatograms
of the DB samples recorded at wavelengths within 190–500
nm. A typical UPLC chromatogram of DB sample at 280
nm is shown in Figure 2.
The mass spectrometric conditions were optimized in
both positive and negative ion modes; the positive ion
mode was found to be more sensitive. In order to pro-
mote the formation of quasi-molecular ions [M+H] + in
MS analysis, 0.1% formic acid was used in the mobile
phase. MS offset voltage was further adjusted to generate
















Figure 2 Typical UPLC chromatogram of DB sample using PDA at 280 nm.
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Herbal medicine is a multicomponent system with many
unknown components, and the chromatographic peaks
often overlap when a sample of an herbal medicine is
eluted on a column. The retention time of the analytes can
vary between different laboratories, while the UV spectra
of the active components and other analogues are greatly
similar. Thus, the direct identification of the target com-
pounds merely based on the chromatographic parameters
is still a challenge in many cases.
Compared to chromatography, mass spectrometry can
provide more exclusive molecular information on the target
compounds by elucidating their fragmentation pathways.
These MS fragmentation characteristics greatly contribute
to identify the active components from the complex mix-
ture of herbal medicine even if the standard compounds
are unavailable. Therefore, precise MS characterization of
the six flavonoids is necessary in this study.
Based on comparison with chromatograms and MS frag-
ments of standard compounds, six peaks in the DB sample
chromatogram were unambiguously identified as dracorho-
din (1), 4,6-dihydroxy-2- methoxy-3-methyldihydrochalcone
(2), 4,6-dihydroxy-2-methoxy-3-methylchalcone (3), (2S)-5,
7- dihydroxy-dihydroflavone (4), (2S)-5-methoxyflavan-7-ol
(5) and (2S)-5-methoxy-6-methylflavan- 7-ol (6). From the
results, it is obvious that the major types of constituents in
DB are flavonoids, including anthocyanins, chalcones, flava-
nones and flavans. The extracted ion chromatogram (EIC)
MS spectra and the proposed fragmentation pathways of the
six flavonoids are shown in Figure 3.
Under the MS conditions, dracorhodin (peak 1) is more
stable than other components, and it is not easy for dra-
corhodin to generate new characteristic fragment ions.
Chalcones (peak 2 and peak 3) lose a common molecule
of H2O (−18 Da) forming their [M + H]
+ ions, while the
fragments of m/z 167 (C9H11O3) and m/z 105 (C7H5O)
are the characteristic ions of peak 2 and peak 3, respect-
ively. Flavanone (peak 4) and flavans (peaks 5 and 6) lose a
common molecule of C8H8 (−104 Da) to generate their
characteristic fragment ions of m/z 153 (C7H5O4), m/z153 (C8H9O3) and m/z 167 (C9H11O3), respectively [17].
The detailed elemental composition of the fragments is
summarized in Table 2, and the mass errors between the
observed and calculated values of molecular weight of the
fragments are found to be less than 10 mDa. The results
demonstrate that the developed UPLC-MS method is
specific and precise, and therefore is suitable for the
characterization of the flavonoids in DB medicine.
Method validation
Validation of the developed method was conducted, and
the results are summarized in Tables 1 and 3. Linearity
was determined with five data points over the concentra-
tion range. For all of the analytes, good linear calibrations
were achieved over the selected concentration range with
R2 > 0.99. At a signal-to-noise ratio of 3:1, the limits of de-
tection (LOD) of the quantified components were found
to be within the range 0.06–0.83 ng. The instrumental
precision and method repeatability were evaluated, and
the relative standard deviation (RSD) values were found to
be within the range of 0.8 to 2.5% for the instrumental
precision test and of 1.4 to 3.8% for the method repeatabil-
ity test. The accuracy of the method was validated by the
determination of recovery. Recovery study was conducted
using a DB sample spiked with approximately 50, 100 and
200% of known amounts of analytes in the samples. The
spiked samples were then extracted and quantified in
accordance with the established procedures. Triplicate
sample analysis was conducted for the determination of re-
covery at each spiked level. The recoveries of all of the ana-
lytes were within the range 94.2–102.8% with RSD ≤ 4.9%.
The results show that the overall procedure is precise and
accurate, and therefore is suitable for the quantitative ana-
lysis of DB samples.
Sample analysis
The “Dragon’s Blood” (DB) samples collected from dif-
ferent regions were assessed by the present method, and









































































































































































Figure 3 EIC-MS spectra and proposed fragmentation pathways of the six components.
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http://journal.chemistrycentral.com/content/6/1/116Firstly, there is a significant variation in the contents of
the quantified components in DB samples. Such variations
may be mainly due to processing of the raw material.
According to the literature [19], Daemonorops draco is a
plant indigenous to Indonesia and Malaysia, and the resinTable 2 Elemental composition of major fragments in the MS
Peak RT (min) Compounds
1 4.9 Dracorhodin
2 8.9 4,6-Dihydroxy-2-methoxy- 3-methyldihydrochalcone
3 9.4 4,6-Dihydroxy-2-methoxy- 3-methylchalcone
4 10.1 (2S)-5,7-Dihydroxy- dihydroflavone
5 12.8 (2S)-5-Methoxyflavan-7-ol
6 13.4 (2S)-5-Methoxy-6-methyl- flavan-7-oldirectly collected from the fruit of Daemonorops draco
tree is called raw “Dragon’s Blood” (DB). Before being sold
in markets and used in clinics, the raw DB is processed to
remove fruit pulp residue, and it is shaped by the addition
of excipients, such as albane and dammar. However, thespectra
Formula Calculated (m/z) Observed (m/z) Error (mDa)
C17H15O3 267.1016 267.1083 6.7
C16H12O3 252.0781 252.0814 3.3
C17H18O4Na 309.1097 309.1098 0.1
C17H19O4 287.1278 287.1274 −0.4
C17H17O3 269.1172 269.1186 1.4
C9H11O3 167.0703 167.0779 7.6
C17H16O4Na 307.0941 307.0940 −0.1
C17H17O4 285.1121 285.1133 1.2
C17H15O3 267.1016 267.1051 3.5
C7H5O 105.0335 105.0385 5.0
C15H12O4Na 279.0628 279.0630 0.2
C15H13O4 257.0808 257.0838 3.0
C7H5O4 153.0182 153.0242 6.0
C16H16O3Na 279.0992 279.1017 2.5
C16H17O3 257.1172 257.1188 1.6
C8H9O3 153.0546 153.0616 7.0
C17H18O3Na 293.1148 293.1152 0.4
C17H19O3 271.1329 271.1341 1.2
C9H11O3 167.0703 167.0782 7.9
Table 3 Precision and accuracy study of the method
Peak Compounds Precision (RSD %, n = 6) Accuracy (RSD %, n = 3)
Instrument Repeatability Low Medium High
1 Dracorhodin 1.3 1.4 102.8 (2.2) 96.2 (2.5) 98.2 (2.3)
2 4,6-Dihydroxy-2-methoxy-3- methyldihydrochalcone 0.8 2.1 94.2 (3.2) 94.7 (1.8) 95.3 (3.4)
3 4,6-Dihydroxy-2-methoxy-3- methylchalcone 1.6 3.1 99.3 (2.0) 97.7 (3.5) 100.6 (2.5)
4 (2S)-5,7-Dihydroxy- dihydroflavone 0.9 2.7 102.7 (2.8) 96.1 (1.9) 96.4 (4.9)
5 (2S)-5-Methoxyflavan-7-ol 2.5 3.8 99.9 (3.8) 101.0 (2.0) 99.8 (3.7)
6 (2S)-5-Methoxy-6- methylflavan-7-ol 1.5 2.7 101.5 (4.5) 99.8 (2.9) 98.7 (4.5)
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http://journal.chemistrycentral.com/content/6/1/116cost of DB is high while the cost of the excipients is low. It is
hard to tell from appearance how much true DB is in any
given sample sold on the market. Hence, there is an attempt
to adding more excipients into the DB, and sell it for more
profit. The generally low contents of all quantified constitu-
ents in some DB samples can be attributed to this reason. On
the other hand, this finding confirms the necessity of develop-
ing a comprehensive quality evaluation standard based on the
quantitation of the active components and on novel analysis
technology to ensure the quality of DB medicine.
Secondly, comparison of the contents of the six ana-
lytes shows that the total amounts of dracorhodin (peak
1), (2S)-5-methoxyflavan-7-ol (peak 5) and (2S)-5-meth-
oxy-6-methylflavan-7-ol (peak 6) represent about 90% of
the total quantified compounds. It is undoubted that
dracorhodin applicable as markers for quality evaluation
of DB, due to that it is an identified bioactive component
[1]. In recent years, the anti-platelet effects of flavonoids
have been confirmed by many reports in the literature
[20-22], and laboratory studies suggest that “Dragon’s
Blood” species exert their clinical effects by inhibiting













DB1 Hong Kong 1.69 0.78
DB2 Hong Kong 0.93 1.11
DB3 Hong Kong 4.76 0.98
DB4 Hong Kong 0.77 0.21
DB5 Hong Kong 0.41 0.93
DB6 Beijing 15.71 10.58
DB7 Chengdu 16.46 5.69
DB8 Chengdu 8.49 2.90
DB9 Chengdu 2.64 7.85
DB10 Tianjin 30.24 17.78
DB11 Tianjin 3.04 4.63
DB12 Jilin 22.10 13.66(2S)-5-methoxyflavan-7-ol and (2S)-5-methoxy-6-methyl-
flavan-7-ol have been reported [9,23], and the underlying
mechanism for anti-platelet activity of (2S)-5-methoxy-6-
methylflavan-7-ol was related to inhibition of TXA2 for-
mation via the inhibition of COX. Based on our research
results and these reports, we believe that dracorhodin,
(2S)-5-methoxyflavan-7-ol and (2S)-5-methoxy-6-methyl-
flavan-7-ol can well represent the active flavonoids of DB
to be responsible for the clinical effects of “Dragon’s
Blood” against blood stasis.
Therefore, to reflect the roles of multiple compounds for
the therapeutic functions, dracorhodin, (2S)-5-methoxyflavan-
7-ol and (2S)-5-methoxy-6-methylflavan-7-ol should be
chosen as analytical markers for a more comprehensive qual-
ity evaluation of DB medicine. The present hyphenation
method could meet this need, making a simultaneous ana-
lysis of the three active components in a single run possible.
Conclusions
A UPLC-PAD-MS method was developed for the simultan-
eous analysis of six flavonoids in the ethnomedicine “Dragon’s
















1.14 0.49 24.79 4.98
0.46 0.47 21.01 6.60
0.28 0.24 13.07 4.38
0.06 0.02 4.18 3.03
0.13 0.11 7.66 4.42
4.22 2.65 87.94 23.88
1.36 1.21 59.32 20.01
1.27 0.85 42.67 11.81
0.26 1.44 58.78 13.70
1.84 3.98 167.64 47.38
1.96 1.30 41.78 23.48
3.19 13.58 83.23 58.80
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http://journal.chemistrycentral.com/content/6/1/116online ESI-MS, and then were quantified by PAD. With re-
spect to already existing methods, the present hyphenation
procedure is highly efficient and reliable, and hence suitable
for qualitative and quantitative analysis of DB samples.
Based on the determination results, it is suggested that
three major active components among the six flavonoids,
namely dracorhodin, (2S)-5-methoxyflavan-7-ol and
(2S)-5-methoxy-6- methylflavan-7-ol, be used as the
index for quality evaluation of DB medicine.
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